Report
Julien Onillon
EUR 250.00 For Business Accounts Only

ESI Group: Stratospheric multiples

Who says ESI Group is overvalued? The share price of the small software company specializing in virtual prototyping has double since the bottom of the Covid crisis, but its large competitors in Europe and the US performed as well, or even better. ESI Group is trading at just over 21x its EBITDA 2021 but Dassault Systèmes, is valued at 31x its EBITDA. On the same multiple, its American competitors Ansys and Altair are respectively trading at 41x and 111x. The PLM and virtual prototyping software industry undoubtedly has a great future ahead of it, but are these valuations multiples justified? We don’t think so, in particular for ESI Group.

Underlying
ESI Group SA

ESI Group is engaged in researching, developing, designing, creating and distributing computer software; and acquiring, receiving, holding, managing and trading in a portfolio of securities, especially in fields related to the publishing of scientific software, including digital simulation software for prototyping and manufacturing processes and related decision-making support tools.

Provider
LPE Research
LPE Research

LPE Research is a new independent equity research firm offering research on demand to fund managers. 

We believe our independent equity research on demand model dedicated to fund managers is the future, that our disruptive equity research on demand model will save money and addresses fund managers real needs, that fund managers should pay only for the equity research they need and if it creates value for them. And we ambition to become fund managers primary outperformance partner.

Our equity research services on demande services are:
- Stock conviction: independent reports
- Stock checking: on demand financial analysis
- Stock coverage: alert and coverage of specific companies
- Stock ideas (to come): list of investment opportunities

Analysts
Julien Onillon

Other Reports on these Companies
Other Reports from LPE Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch